Gregory Sullivan, M.D.

Chief Medical Officer

Dr. Sullivan has been an integral part of Tonix Pharmaceuticals since 2014 and currently serves as the Chief Medical Officer. Prior to Tonix, he most recently worked as an Assistant Professor of Psychiatry in the Department of Psychiatry at Columbia University Medical Center, a Research Scientist at the New York State Psychiatric Institute (NYSPI), and as a practicing psychiatrist.

Dr. Sullivan’s areas of expertise include the diagnosis, treatment and neurobiology of anxiety and mood disorders, including PTSD. As Principal Investigator and Co-Investigator on many human studies of PTSD, panic disorder, and bipolar and unipolar depression, he has administered the recruitment, biological assessments, treatment, and safety of participants with central nervous system disorders in clinical trials. He has published more than 50 articles and chapters on research topics ranging from stress and anxiety disorders to abnormal serotonergic receptor expression in bipolar depression, PTSD and panic disorder. He previously served as a member of the Institutional Review Board of the NYSPI from 2009 to 2014. He is a recipient of grants from the National Institute of Mental Health, the Anxiety Disorders Association of America, the American Foundation for Suicide Prevention, and NARSAD.

Dr. Sullivan completed his NIMH-sponsored Research Training Fellowship in Affective and Anxiety Disorders at Columbia University. During his fellowship, Dr. Sullivan studied with Dr. Joseph LeDoux at New York University to develop translational animal models of anxiety disorders for preclinical testing of novel anxiolytic therapies. Dr. Sullivan received his medical doctorate from the College of Physicians & Surgeons at Columbia University and completed his residency training in psychiatry at Columbia University Medical Center. Dr. Sullivan earned his bachelor’s degree from the University of California, Berkeley in biological sciences.